An Introduction to Clinical Trials in the MENA Region: Opportunity Meets Complexity

What if one of the world’s most underutilised regions in clinical research held the key to faster, more diverse, and cost-effective trials?

The Middle East and North Africa (MENA) region is increasingly attracting global attention. With a growing population, evolving regulatory frameworks, and rising healthcare investment, it is quickly becoming a strategic destination for clinical trials. Yet, many organisations are still unsure how to navigate this complex landscape.

Why MENA Matters Now

Historically, the MENA region has been underrepresented in global clinical research, contributing to less than 1% of trials despite significant population size and disease burden.

That is beginning to change.

Today, the region is experiencing steady growth in clinical trial activity, driven by:

• Large and diverse patient populations, supporting faster recruitment and broader data sets
• Rising prevalence of chronic and genetic diseases, creating demand for innovative treatments
• Lower operational costs compared to Western markets
• Government investment and healthcare transformation initiatives

In fact, the MENA clinical trials market is projected to grow steadily through the coming years, reflecting increasing global interest.

A Rapidly Evolving Regulatory Landscape

One of the defining features of clinical trials in MENA is regulatory diversity.

Each country has its own approval processes, ethics committees, and submission requirements. This fragmented landscape can create challenges for sponsors unfamiliar with local systems.

However, there is clear progress:

• Regulatory frameworks are becoming more structured and transparent
• Some countries are adopting accelerated approval pathways
• Increased alignment with international standards is improving trial feasibility

Understanding these differences, and knowing how to work with them, is essential for successful study start-up.

Key Opportunities for Sponsors and CROs

For organisations willing to invest in local knowledge, the MENA region offers significant advantages:

• Faster patient recruitment due to treatment-naïve populations
• Access to unique genetic profiles, particularly valuable in rare disease research
• Improving infrastructure and clinical expertise
• Strong collaboration potential with regional institutions and authorities

These factors make MENA particularly attractive for Phase II and III trials, as well as for studies requiring diverse patient populations.

Challenges to Consider

Despite the opportunities, there are still hurdles to navigate:

• Regulatory variability across countries
• Differences in site experience and training levels
• Logistical complexities, including importation of investigational products
• Need for strong local partnerships

Success in the region depends on preparation, cultural awareness, and regulatory insight.

The Future of Clinical Trials in MENA

The trajectory is clear: MENA is transitioning from an emerging region to a strategic player in global clinical development.

Advances in digital health, decentralised trials, and regional collaboration are expected to further accelerate growth. At the same time, ongoing regulatory reforms will continue to improve efficiency and reliability.

For clinical research professionals, this presents both an opportunity, and a necessity, to build expertise in the region.

Learn More

If you’re looking to deepen your understanding of clinical trials in this rapidly evolving region, our course provides practical insights into regulatory requirements, operational challenges, and strategic opportunities across MENA.

Whether you're new to the region or expanding your clinical portfolio, this course will help you navigate MENA with confidence.

Published on Apr 01, 2026 by Simóne Blair